Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer

• Conditions: Rectal Neoplasm

• Registration Number: NCT02630056
• Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Brief Summary

The purpose of this study is to validate the dosimetric parameters that correlate with acute hematologic toxicity (HT) in patients with rectal cancer treated with neoadjuvant chemoradiotherapy.

Detailed Description

The investigators' ongoing retrospective study investigated the clinical and dosimetric parameter (dosimetry of pelvic bone marrow) which relate with acute hematologic toxicity in patient with rectal cancer treated with neoadjuvant chemoradiotherapy. In order to validate the dosimetric limitation of pelvic bone marrow in decreasing the intensity of HT, the investigators want to conduct a study to observe the acute HT without assigning any specific interventions to the subjects of the study, who will receive the standard treatment according to the multidisciplinary team's (MDT) decision and patient choice. Therefore, this study's type is observational.

Study Timeline

• Status Verified: 2015-11
• Study First Submitted: 2015-11-27
• Study Start: 2015-12
• Study First Submitted QC: 2015-12-14
• Last Update Submitted: 2015-12-14
• Study First Posted: 2015-12-15
• Last Update Posted: 2015-12-15
• Primary Completion: 2017-08
• Study Completion: 2017-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 90

Inclusion Criteria

• rectal cancer
• receive neoadjuvant chemoradiotherapy

Exclusion Criteria

• hematological system disorders

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
the grade of acute hematologic toxicity	5-6 weeks	Hematologic Adverse Events That Are Related to Pelvic Bone Marrow Irradiation